Biosyngen has unveiled its cutting-edge strategies for next-generation tumour-infiltrating lymphocyte (TIL) therapies at the Asia Bio Innovation Summit 2025 in Singapore. The event, which gathered 30 world-class speakers, 10 exhibitors, and 200 attendees, focused on antibody-drug conjugates (ADCs) and cell and gene therapies (CGT), fostering global collaboration in the biopharmaceutical sector.
Dr Mingyu Liu, a senior research and development scientist at Biosyngen, delivered a keynote address highlighting the challenges and strategies in TIL therapy development. He noted that whilst TIL therapy shows promise in treating cancers like advanced melanoma and cervical cancer, its efficacy in other solid tumours remains limited. Biosyngen’s approach includes a high-efficiency TIL expansion process, enabling robust expansion from both surgical and biopsy samples whilst preserving antitumour activity. This innovation addresses the difficulty of obtaining surgical samples from late-stage cancer patients.
Additionally, Biosyngen has developed proprietary rapid expansion protocols that increase central memory T cells by eightfold, maintaining optimal CD8 T cell ratios for durable therapeutic effects. The company also employs gene editing through a lentiviral transfection system to enhance TIL functionality, achieving a transduction efficiency exceeding 50%. Furthermore, Biosyngen enriches tumour antigen-specific T cells using selective expansion techniques, improving clinical response rates.
Following the Singapore summit, the Asia Bio Innovation Summit will continue in Chengdu and Shenzhen, focusing on regional biopharma policies and industry-academia collaboration. Experts agree that ADC and CGT technologies will be pivotal in oncology innovation over the next decade, with Asia emerging as a global leader in biopharmaceutical breakthroughs.
“`
